Impact of conjugation strategies for targeting of antibodies in gold nanoparticles for ultrasensitive detection of 17β-estradiol

Oliveira, Jairo Pinto de; Prado, Adilson Ribeiro; Keijok, Wanderson Juvencio; Antunes, Paulo Wagnner Pereira; Yapuchura, Enrique R.; Guimarães, Marco César Cunegundes

doi:10.1038/s41598-019-50424-5

Cited by 112 publications

(88 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NP functionalization with antibodies or antibody fragments can be carried out mainly via the adsorption phenomenon, covalent-nature binding, or binding by the use of adapter molecules (Figure 1). The immobilization of antibodies into the nanoparticle surface must guarantee both the desired amount of antibodies per nanoparticle and the proper antibody orientation [43,44]. Additionally, the immobilization method must generate a stable bond and preserve the biological activity of the antibody [45].…”

Section: Conjugation Strategies For Acnp Generationmentioning

confidence: 99%

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Nanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating cancer. Active targeting NPs can be generated by conjugation with ligands that bind overexpressed or mutant cell surface receptors on target cells that are poorly or not even expressed on normal cells. Receptor-mediated endocytosis of the NPs occurs and the drug is released inside the cell or in the surrounding tissue due to the bystander effect. Antibodies are the most frequently used ligands to actively target tumor cells. In this context, antibody-based therapies have been extensively used in HER2+ breast cancer. However, some patients inherently display resistance and in advanced stages, almost all eventually progress. Functionalized NPs through conjugation with antibodies appear to be a promising strategy to optimize targeted therapies due to properties related to biocompatibility, suitable delivery control and efficiency of functionalization. This review is focused on the different strategies to conjugate antibodies into polymeric NPs. Recent antibody conjugation approaches applied to the improvement of breast cancer therapy are highlighted in this review.

show abstract

Section: Conjugation Strategies For Acnp Generationmentioning

confidence: 99%

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The immobilization of antibodies should ensure the desired amount of these biomolecules per nanoparticle and their correct orientation [ 39 ]. The higher the ratio of antibody molecules over the NP surface, the lower the spatial accessibility of the antigen that is present [ 40 ]. Moreover, the coupling method must maintain the biological activity of the antibody [ 41 ].…”

Section: Selective Targeting Of Breast Tumorsmentioning

confidence: 99%

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

Juan

Cimas

Bravo³

et al. 2020

IJMS

View full text Add to dashboard Cite

Breast cancer is the most common invasive tumor in women and the second leading cause of cancer-related death. Nanomedicine raises high expectations for millions of patients as it can provide better, more efficient, and affordable healthcare, and it has the potential to develop novel therapeutics for the treatment of solid tumors. In this regard, targeted therapies can be encapsulated into nanocarriers, and these nanovehicles are guided to the tumors through conjugation with antibodies—the so-called antibody-conjugated nanoparticles (ACNPs). ACNPs can preserve the chemical structure of drugs, deliver them in a controlled manner, and reduce toxicity. As certain breast cancer subtypes and indications have limited therapeutic options, this field provides hope for the future treatment of patients with difficult to treat breast cancers. In this review, we discuss the application of ACNPs for the treatment of this disease. Given the fact that ACNPs have shown clinical activity in this clinical setting, special emphasis on the role of the nanovehicles and their translation to the clinic is placed on the revision.

show abstract

“…The different strategies that have been pursued to anchor Tmab to the surface of sundry types of NPs and liposomes can be classified into two main groups, depending on whether or not the antibody-binding is covalent. In this way, works in which Tmab has been adsorbed on several particulate nanosystems can be found in the literature, while in other studies the antibody has been covalently attached to NPs and liposomes following several strategies, such as with carbodiimide, maleimide, or click-chemistry [17,38].…”

Section: Nanoparticle and Liposome Functionalization With Trastuzumabmentioning

confidence: 99%

Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine

2020

View full text Add to dashboard Cite

HER2 overexpression, which occurs in a fifth of diagnosed breast cancers as well as in other types of solid tumors, has been traditionally linked to greater aggressiveness. Nevertheless, the clinical introduction of trastuzumab has helped to improve HER2-positive patients’ outcomes. As a consequence, nanotechnology has taken advantage of the beneficial effects of the administration of this antibody and has employed it to develop HER2-targeting nanomedicines with promising therapeutic activity and limited toxicity. In this review, the molecular pathways that could be responsible for trastuzumab antitumor activity will be briefly summarized. In addition, since the conjugation strategies that are followed to develop targeting nanomedicines are essential to maintaining their efficacy and tolerability, the ones most employed to decorate drug-loaded nanoparticles and liposomes with trastuzumab will be discussed here. Thus, the advantages and disadvantages of performing this trastuzumab conjugation through adsorption or covalent bindings (through carbodiimide, maleimide, and click-chemistry) will be described, and several examples of targeting nanovehicles developed following these strategies will be commented on. Moreover, conjugation methods employed to synthesized trastuzumab-based antibody drug conjugates (ADCs), among which T-DM1 is well known, will be also examined. Finally, although trastuzumab-decorated nanoparticles and liposomes and trastuzumab-based ADCs have proven to have better selectivity and efficacy than loaded drugs, trastuzumab administration is sometimes related to side toxicities and the apparition of resistances. For this reason also, this review focuses at last on the important role that newer antibodies and peptides are acquiring these days in the development of HER2-targeting nanomedicines.

show abstract

Impact of conjugation strategies for targeting of antibodies in gold nanoparticles for ultrasensitive detection of 17β-estradiol

Cited by 112 publications

References 30 publications

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine

Contact Info

Product

Resources

About